{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:56:25Z","timestamp":1788494185968,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma A\/S","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40257-025-00985-1","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:05:03Z","timestamp":1761041103000},"page":"149-166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials"],"prefix":"10.1007","volume":"27","author":[{"given":"Tiffany","family":"Mayo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Esdaile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kabashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Kircik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Bennike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"von Eyben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta C.","family":"Martel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads A.","family":"R\u00f8pke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norito","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew F.","family":"Alexis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"10023","key":"985_CR1","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","volume":"387","author":"S Weidinger","year":"2016","unstructured":"Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109\u201322.","journal-title":"Lancet"},{"issue":"5","key":"985_CR2","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s40257-023-00797-1","volume":"24","author":"VL Quan","year":"2023","unstructured":"Quan VL, Erickson T, Daftary K, Chovatiya R. Atopic dermatitis across shades of skin. Am J Clin Dermatol. 2023;24(5):731\u201351.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"985_CR3","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.jaci.2021.09.015","volume":"148","author":"EA Croce","year":"2021","unstructured":"Croce EA, Levy ML, Adamson AS, Matsui EC. Reframing racial and ethnic disparities in atopic dermatitis in Black and Latinx populations. J Allergy Clin Immunol. 2021;148(5):1104\u201311.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"985_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.anai.2018.11.015","volume":"122","author":"PM Brunner","year":"2019","unstructured":"Brunner PM, Guttman-Yassky E. Racial differences in atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122(5):449\u201355.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"985_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/jid.2010.251","volume":"131","author":"TE Shaw","year":"2011","unstructured":"Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 national survey of children\u2019s health. J Investig Dermatol. 2011;131(1):67\u201373.","journal-title":"J Investig Dermatol"},{"issue":"3","key":"985_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.det.2023.02.003","volume":"41","author":"W Adawi","year":"2023","unstructured":"Adawi W, Cornman H, Kambala A, Henry S, Kwatra SG. Diagnosing atopic dermatitis in skin of color. Dermatol Clin. 2023;41(3):417\u201329.","journal-title":"Dermatol Clin"},{"issue":"6","key":"985_CR7","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.jaad.2022.03.067","volume":"87","author":"S McKenzie","year":"2022","unstructured":"McKenzie S, Brown-Korsah JB, Syder NC, Omar D, Taylor SC, Elbuluk N. Variations in genetics, biology, and phenotype of cutaneous disorders in skin of color. Part II: differences in clinical presentation and disparities in cutaneous disorders in skin of color. J Am Acad Dermatol. 2022;87(6):1261\u201370.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"985_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/DER.0000000000000323","volume":"29","author":"S Narla","year":"2018","unstructured":"Narla S, Hsu DY, Thyssen JP, Silverberg JI. Predictors of hospitalization, length of stay, and costs of care among adult and pediatric inpatients with atopic dermatitis in the United States. Dermatitis. 2018;29(1):22\u201331.","journal-title":"Dermatitis"},{"issue":"8","key":"985_CR9","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1001\/jamadermatol.2019.0597","volume":"155","author":"J Wan","year":"2019","unstructured":"Wan J, Margolis DJ, Mitra N, Hoffstad OJ, Takeshita J. Racial and ethnic differences in atopic dermatitis-related school absences among US children. JAMA Dermatol. 2019;155(8):973\u20135.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"985_CR10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/1346-8138.14116","volume":"45","author":"W Wei","year":"2018","unstructured":"Wei W, Anderson P, Gadkari A, Blackburn S, Moon R, Piercy J, et al. Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis. J Dermatol. 2018;45(2):150\u20137.","journal-title":"J Dermatol"},{"issue":"7","key":"985_CR11","doi-asserted-by":"publisher","first-page":"776","DOI":"10.36849\/JDD.2020.4937","volume":"19","author":"C Grayson","year":"2020","unstructured":"Grayson C, Heath CR. Dupilumab improves atopic dermatitis and post-inflammatory hyperpigmentation in patient with skin of color. J Drugs Dermatol. 2020;19(7):776\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"985_CR12","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jaad.2018.09.035","volume":"80","author":"YW Yew","year":"2019","unstructured":"Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol. 2019;80(2):390\u2013401.","journal-title":"J Am Acad Dermatol"},{"issue":"6S","key":"985_CR13","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1097\/DER.0000000000000864","volume":"33","author":"V Aoki","year":"2022","unstructured":"Aoki V, Oliveira M, Wegzyn C, Desai SR, Jewell S, Ladizinski B, et al. Assessment and monitoring challenges among patients with moderate-to-severe atopic dermatitis across Fitzpatrick skin types: a photographic review and case series. Dermatitis. 2022;33(6S):S24\u201336.","journal-title":"Dermatitis"},{"issue":"4","key":"985_CR14","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/exd.13514","volume":"27","author":"BP Kaufman","year":"2018","unstructured":"Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups-variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018;27(4):340\u201357.","journal-title":"Exp Dermatol"},{"issue":"4","key":"985_CR15","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jaad.2021.12.062","volume":"87","author":"K Shao","year":"2022","unstructured":"Shao K, Hooper J, Feng H. Racial and ethnic health disparities in dermatology in the United States. Part 2: disease-specific epidemiology, characteristics, management, and outcomes. J Am Acad Dermatol. 2022;87(4):733\u201344.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"985_CR16","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.3390\/jcm12113805","volume":"12","author":"R Bissonnette","year":"2023","unstructured":"Bissonnette R, Jankicevic J, Saint-Cyr Proulx E, Maari C. Ethnicity, race and skin color: challenges and opportunities for atopic dermatitis clinical trials. J Clin Med. 2023;12(11):3805.","journal-title":"J Clin Med"},{"issue":"10247","key":"985_CR17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360.","journal-title":"Lancet"},{"issue":"7","key":"985_CR18","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","volume":"139","author":"LC Tsoi","year":"2019","unstructured":"Tsoi LC, Rodriguez E, Degenhardt F, Baurecht H, Wehkamp U, Volks N, et al. Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis. J Investig Dermatol. 2019;139(7):1480\u20139.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"985_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/all.15845","volume":"79","author":"E Del Duca","year":"2024","unstructured":"Del Duca E, He H, Liu Y, Pagan AD, David E, Cheng J, et al. Intrapatient comparison of atopic dermatitis skin transcriptome shows differences between tape-strips and biopsies. Allergy. 2024;79(1):80\u201392.","journal-title":"Allergy"},{"issue":"1","key":"985_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jaci.2021.01.001","volume":"148","author":"Y Renert-Yuval","year":"2021","unstructured":"Renert-Yuval Y, Del Duca E, Pavel AB, Fang M, Lefferdink R, Wu J, et al. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. J Allergy Clin Immunol. 2021;148(1):148\u201363.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"985_CR21","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","volume":"136","author":"S Noda","year":"2015","unstructured":"Noda S, Suarez-Farinas M, Ungar B, Kim SJ, de Guzman Strong C, Xu H, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 2015;136(5):1254\u201364.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"985_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.anai.2018.08.024","volume":"122","author":"RD Sanyal","year":"2019","unstructured":"Sanyal RD, Pavel AB, Glickman J, Chan TC, Zheng X, Zhang N, et al. Atopic dermatitis in African American patients is T(H)2\/T(H)22-skewed with T(H)1\/T(H)17 attenuation. Ann Allergy Asthma Immunol. 2019;122(1):99\u2013110 (e6).","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"985_CR23","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.19573","volume":"184","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450\u201363.","journal-title":"Br J Dermatol"},{"issue":"3","key":"985_CR24","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437\u201349.","journal-title":"Br J Dermatol"},{"issue":"6","key":"985_CR25","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","volume":"159","author":"AS Paller","year":"2023","unstructured":"Paller AS, Flohr C, Cork M, Bewley A, Blauvelt A, Hong HC, et al. Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial. JAMA Dermatol. 2023;159(6):596\u2013605.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"985_CR26","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1001\/jamadermatol.2023.2626","volume":"159","author":"JF Merola","year":"2023","unstructured":"Merola JF, Butler DC, Mark T, Schneider S, Kim Y, Abuabara K. Safety and efficacy of tralokinumab in older adults with moderate-to-severe atopic dermatitis: a secondary analysis. JAMA Dermatol. 2023;159(10):1119\u201323.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"985_CR27","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jaad.2022.07.019","volume":"87","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Langley RG, Lacour JP, Toth D, Laquer V, Beissert S, et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022;87(4):815\u201324.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"985_CR28","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40257-022-00702-2","volume":"23","author":"JI Silverberg","year":"2022","unstructured":"Silverberg JI, Adam DN, Zirwas M, Kalia S, Gutermuth J, Pinter A, et al. Tralokinumab plus topical corticosteroids as needed provides progressive and sustained efficacy in adults with moderate-to-severe atopic dermatitis over a 32-week period: an ECZTRA 3 post hoc analysis. Am J Clin Dermatol. 2022;23(4):547\u201359.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"985_CR29","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s40257-023-00806-3","volume":"24","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Pink AE, Blauvelt A, Gooderham M, Armstrong AW, Worm M, et al. Tralokinumab efficacy over 1 year in adults with moderate-to-severe atopic dermatitis: pooled data from two phase III trials. Am J Clin Dermatol. 2023;24(6):939\u201352.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"985_CR30","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jaad.2022.11.047","volume":"88","author":"LA Beck","year":"2023","unstructured":"Beck LA, Bieber T, Weidinger S, Tauber M, Saeki H, Irvine AD, et al. Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: analysis of microbial diversity in ECZTRA 1, a randomized controlled trial. J Am Acad Dermatol. 2023;88(4):816\u201323.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"985_CR31","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1111\/all.16108","volume":"79","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E, Kabashima K, Staumont-Salle D, Nahm WK, Pauser S, Da Rosa JC, et al. Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years. Allergy. 2024;79(6):1560\u201372.","journal-title":"Allergy"},{"issue":"1","key":"985_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/bjd.18565","volume":"183","author":"N Katoh","year":"2020","unstructured":"Katoh N, Kataoka Y, Saeki H, Hide M, Kabashima K, Etoh T, et al. Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials. Br J Dermatol. 2020;183(1):39\u201351.","journal-title":"Br J Dermatol"},{"issue":"4","key":"985_CR33","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","volume":"147","author":"Y Renert-Yuval","year":"2021","unstructured":"Renert-Yuval Y, Thyssen JP, Bissonnette R, Bieber T, Kabashima K, Hijnen D, et al. Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council. J Allergy Clin Immunol. 2021;147(4):1174-90.e1.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"985_CR34","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.jaci.2018.02.047","volume":"142","author":"HC Wen","year":"2018","unstructured":"Wen HC, Czarnowicki T, Noda S, Malik K, Pavel AB, Nakajima S, et al. Serum from Asian patients with atopic dermatitis is characterized by T(H)2\/T(H)22 activation, which is highly correlated with nonlesional skin measures. J Allergy Clin Immunol. 2018;142(1):324\u20138 (e11).","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"985_CR35","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jaci.2019.06.044","volume":"145","author":"K Abuabara","year":"2020","unstructured":"Abuabara K, You Y, Margolis DJ, Hoffmann TJ, Risch N, Jorgenson E. Genetic ancestry does not explain increased atopic dermatitis susceptibility or worse disease control among African American subjects in 2 large US cohorts. J Allergy Clin Immunol. 2020;145(1):192\u20138 (e11).","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"985_CR36","first-page":"804","volume":"18","author":"AF Alexis","year":"2019","unstructured":"Alexis AF, Rendon M, Silverberg JI, Pariser DM, Lockshin B, Griffiths CE, et al. Efficacy of dupilumab in different racial subgroups of adults with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials. J Drugs Dermatol. 2019;18(8):804\u201313.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"985_CR37","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.anai.2023.11.002","volume":"132","author":"AF Alexis","year":"2023","unstructured":"Alexis AF, Silverberg JI, Rice ZP, Armstrong AW, Desai SR, Fonacier L, et al. Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type. Ann Allergy Asthma Immunol. 2023;132(3):383\u20139.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"985_CR38","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","volume":"132","author":"DK Chu","year":"2024","unstructured":"Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, De Benedetto A, Ellison K, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology joint task force on practice parameters GRADE- and institute of medicine-based recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274\u2013312.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"985_CR39","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43\u201356.","journal-title":"J Am Acad Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00985-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00985-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00985-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:51:00Z","timestamp":1769849460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00985-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["985"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00985-1","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tiffany Mayo has served as an investigator or consultant for Eli Lilly and Company, ChemoCentryx, Pfizer, Janssen, Galderma, Bristol Myers Squibb, Acelyrin, Novartis, LEO Pharma, Arcutis, and Procter & Gamble. Jonathan Silverberg reports honoraria as a consultant\/advisory board member from LEO Pharma and has acted as a consultant for and\/or received grants\/honoraria from AbbVie, Alamar, Aldena, Amgen, AnaptysBio, AOBiome, Apollo, Arcutis, Arena, Asana Biosciences, ASLAN, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, Eli Lilly and Company, FIDE, Galderma Research and Development, GlaxoSmithKline, Glenmark, Incyte, Inmagene, Invea, Kiniksa, LEO Pharma, MedImmune, Menlo Therapeutics, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, PuriCore, RAPT, Recludix, Regeneron, Sandoz, Sanofi, Sanofi-Genzyme, Shaperon, TARGET RWE, Teva, Union Therapeutics, and UpToDate. April Armstrong has served as a research investigator and\/or scientific advisor to AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, EPI Health, Incyte, LEO Pharma, UCB, Janssen, Eli Lilly and Company, Nimbus, Novartis, Ortho Dermatologics, Sun Pharma, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and ModMed. Emma Guttman-Yassky has received honoraria for consultant services from AbbVie, Almirall, Amgen, Asana Biosciences, Boehringer Ingelheim, Cara Therapeutics, Celgene, Concert, DBV Technologies, Dermira, DS Biopharma, Eli Lilly and Company, EMD Serono, Escalier, Galderma, Glenmark, Kyowa Kirin, LEO Pharma, Mitsubishi Tanabe, Pfizer, RAPT Therapeutics, Regeneron, Sanofi, Sienna Biopharma, and Union Therapeutics; and received research grants for investigator services from AbbVie, Almirall, Amgen, AnaptysBio, Asana Biosciences, Boehringer Ingelheim, Celgene, Concert, Dermavant, Dermira, DS Biopharma, Eli Lilly and Company, Glenmark, Galderma, Innovaderm, Janssen, Kiniksa, Kyowa Kirin, LEO Pharma, Novan, Pfizer, Ralexar, Regeneron, Sienna Biopharma, UCB, and Union Therapeutics. Andrew Blauvelt has served as a speaker (received honoraria) for Eli Lilly and Company and UCB, has served as a scientific adviser (received honoraria) for AbbVie, Almirall, Alumis, Amgen, AnaptysBio, Apogee, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, Galderma, GlaxoSmithKline, Incyte, IQVIA, Janssen, LEO Pharma, Lipidio, Merck, Novartis, Oruka, Paragon, Pfizer, Regeneron, Sanofi, Spherix Global Insights, Sun Pharma, Takeda, UCB, and Union Therapeutics; has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Almirall, Alumis, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, Galderma, Incyte, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, and UCB; and owns stock in Lipidio and Oruka. Ben Esdaile has served either as an investigator, advisor or speaker for LEO Pharma, L\u2019Or\u00e9al, Thornton & Ross, BIODERMA, Skin + Me, and AbbVie. Kenji Kabashima has received consulting fees or advisory board honoraria from Japan Tobacco Inc., Chugai Pharmaceutical, Maruho, and Pola Pharma; and has received research grants from LEO Pharma, Japan Tobacco Inc., Procter & Gamble Japan, Eli Lilly Japan, Mitsubishi Tanabe Pharma, ONO Pharmaceutical, Kyowa Hakko Kirin, Pola Pharma, AbbVie, Sanofi, and Kyorin Pharmaceutical. Melinda Gooderham has been an investigator, speaker and\/or advisor for: AbbVie, Acelyrin, Amgen, Akros, AnaptysBio, ASLAN, Arcutis, Aristea, Bausch Health, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Dermira, Dermavant, Eli Lilly and Company, Galderma, GlaxoSmithKline, Incyte, Janssen, JAMP Pharma, Kyowa Kirin, LEO Pharma, MedImmune, Merck, Meiji, Moonlake Immunotherapeutics, Nektar, Nimbus, Novartis, Pfizer, Reistone BioPharma, Regeneron, Roche, Sanofi-Genzyme, Sun Pharma, UCB, Union Therapeutics, Ventyx, and Vyne. Leon Kircik has served either as an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Bausch Health Canada, Bristol Myers Squibb, Boehringer Ingelheim, Cellceutix, Celgene, Coherus, Dermavant, Dermira, Eli Lilly and Company, LEO Pharma, MC2, Maruho, Novartis, Ortho Dermatologics, Pfizer, Dr. Reddy's Laboratories, Sun Pharma, UCB, Taro, and Xenoport. Shannon Schneider is an employee of LEO Pharma Inc. Niels Bennike and Rie von Eyben are employees of LEO Pharma A\/S. Mads A. R\u00f8pke was an employee of LEO Pharma A\/S; current affiliation is Novo Nordisk A\/S, Bagsvaerd, Denmark. Britta C. Martel is an employee and shareholder of LEO Pharma A\/S. Norito Katoh has received honoraria as a speaker\/consultant for Sanofi, Maruho, AbbVie, Eli Lilly Japan, Taiho Pharmaceutical, Pfizer, Otsuka Pharmaceutical, and LEO Pharma; and has received grants as an investigator from Mitsubishi Tanabe Pharma, Maruho, Torii Pharmaceutical, AbbVie, and LEO Pharma. Andrew F. Alexis has received grants (funds to institution) from LEO Pharma, Amgen, Arcutis, Dermavant, AbbVie, Castle, Incyte, and Genentech; has served as an advisory board member or consultant for LEO Pharma, Galderma, Pfizer, Sanofi-Regeneron, Dermavant, Beiersdorf, Ortho, L\u2019Oreal, BMS, Bausch health , UCB, Arcutis, Johnson & Johnson, Allergan, Almirall, Abbvie, Amgen, VisualDx, Eli Lilly, Swiss American, Incyte, Castle, Apogee, Canfield, Alphyn, Genentech, Boehringer Ingelheim, Symrise, Novartis, HairDays, Botanix, and Alumis; served as a speaker for Regeneron, Sanofi-Genzyme, L\u2019Or\u00e9al, Janssen, Aerolase, and Scientis; received royalties from Springer, Wiley-Blackwell, Wolters Kluwer Health, and Elsevier; and received equipment from Aerolase.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data underlying this article will be made available upon request to the study sponsor, following review by the external Patient and Scientific Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The ECZTRA 1, 2, 3 and ECZTEND trials were sponsored by LEO Pharma A\/S (Ballerup, Denmark) and conducted in accordance with the ethical principles derived from international guidelines, including the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines, and in compliance with International Council for Harmonization guidelines for Good Clinical Practice. The clinical trials were approved by institutional review boards or ethics committees at each trial site. These trials followed the Consolidated Standards of Reporting Trials reporting guideline.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent for participation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: all authors contributed equally; data curation: Rie von Eyben; Formal Analysis: Rie von Eyben, Britta C. Martel, and Mads R\u00f8pke; funding acquisition: Shannon Schneider; investigation: all authors contributed equally; methodology: Shannon Schneider, Tiffany Mayo, Jonathan I. Silverberg, Andrew Blauvelt, Rie von Eyben, and Britta C. Martel; project administration: Shannon Schneider; resources: Shannon Schneider; software: Rie von Eyben; supervision: Shannon Schneider; validation: Rie von Eyben; visualization: Shannon Schneider; writing\u2014original draft: all authors contributed equally; writing\u2014review and editing: all authors contributed equally.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}